BETHESDA, Md. — After six years of relentless advocacy work, David Mitchell was finally on the cusp of defeating his Goliath — the pharmaceutical industry.
He sat at his desk cranking through his inbox on Friday afternoon, while lawmakers debated a bill he had helped push, the biggest prescription drug pricing reform in two decades. He found yet another interview request at the top. This time, it was from Good Morning America.
Mitchell is a cancer patient and former political public relations expert who volunteered to become the face of the opposition to the pharmaceutical industry during Washington’s lengthy debate on drug pricing. He’s worked twelve-hour days recently, straining to get the Democrats’ drug pricing reform package across the finish line.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect